Karyopharm Therapeutics Inc.

NASDAQ:KPTI

Biotechnology

Healthcare
$7.01 -3.62%

-$0.34 today

Market cap
$158.87M
Beta
0.82
P/E (TTM)
-1.0
EPS (TTM)
-$8.86
52W Low $3.65High $10.99

Volume 0.67M

Average 0.85M

KPTI Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Karyopharm Therapeutics Inc.NASDAQ: KPTI

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 22.01M shares rose 159.9% year over year, ahead of the +72.2% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 22.5% from the prior quarter. Over 3 fiscal years it compounded at +26.1% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +159.9% holds above the trailing-twelve-month pace of +72.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
22.01M+22.5% QoQ
Last fiscal yearDec 2025
10.94M+34.6% YoY
LTMMar 2026
14.32M+72.2% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+159.9%——
1 year+34.6%——
3-year CAGR+26.1%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
10.94M USD
Year-over-year change
+34.6%
4-year CAGR
+21.5%

Weighted Avg Shares vs competitors

How KPTI compares with its peers on the latest reported figures

  • KPTI's LTM Mar 2026 weighted avg shares of 14.32M shares is the lowest of the 4 companies compared; the peer median is 32.45M shares.
  • Its year-over-year change of +72.2% is the 2nd highest of 4, against a peer median of +22.3%.
  • Over three fiscal years its annual growth of +26.1% compares with a peer median of +14.0%.
KPTI Competitors Peer median
Weighted Avg Shares for KPTI and competitors
Company Period LTM YoY 3-year CAGR
XFORX4 Pharmaceuticals, Inc.LTM Mar 202671.88M +965.7%+171.3%
TELOTelomir Pharmaceuticals, Inc. Common StockLTM Mar 202632.45M +9.5%+2.2%
INMBINmune Bio, Inc.LTM Mar 202625.76M +22.3%+14.0%
KPTIKaryopharm Therapeutics Inc.LTM Mar 202614.32M +72.2%+26.1%
Peer median (excluding KPTI) 32.45M+22.3%+14.0%

Competitors are the stored peer set for KPTI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue209.82M157.07M146.03M145.24M146.07M
Cost of Revenue3.4M5.21M4.94M6.01M5.95M
Gross Profit206.42M151.86M141.09M139.23M140.12M
Gross Margin98.4%96.7%96.6%95.9%95.9%
Research & Development160.84M148.66M138.75M143.23M125.62M
Selling, General & Admin143.85M145.4M131.88M115.44M105.21M
Operating Expenses304.69M294.06M270.63M258.67M230.83M
Depreciation & Amortization789K621K530K340K296K
EBITDA(96.99M)(139.31M)(118.42M)(38.6M)(149.85M)
EBITDA Margin-46.2%-88.7%-81.1%-26.6%-102.6%
Operating Income(98.27M)(142.2M)(129.54M)(119.44M)(90.71M)
Operating Margin-46.8%-90.5%-88.7%-82.2%-62.1%
Interest Income582K2.36M10.94M7.4M2.77M
Interest Expense26.05M25M23.82M37.42M45.85M
Other Income / Expenses(25.55M)(22.72M)(13.24M)43.08M(105.29M)
Income Before Tax(123.82M)(164.92M)(142.78M)(76.37M)(196M)
Pre-Tax Margin-59.0%-105.0%-97.8%-52.6%-134.2%
Income Tax Expense268K369K323K57K43K
Net Income(124.09M)(165.29M)(143.1M)(76.42M)(196.04M)
Net Margin-59.1%-105.2%-98.0%-52.6%-134.2%
EPS (Basic)(24.75)(30.28)(18.79)(9.41)(17.93)
EPS (Diluted)(24.75)(30.28)(18.79)(9.41)(17.93)
Weighted Avg Shares5.01M5.46M7.61M8.12M10.94M
Weighted Avg Shares (Diluted)5.01M5.46M7.61M8.12M10.94M

Karyopharm Therapeutics Inc.

NASDAQ:KPTI

Intrinsic Alpha fair value

Locked

Current Price

$7.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.